Resultado de búsqueda
John F Seymour. Professor of Medicine, Director Dept of Haematology Peter MacCallum Cancer Centre & Royal Melbourne. Verified email at petermac.org - Homepage. Hematologic malignancies....
21 de mar. de 2018 · Anderson MA, Deng J, Seymour JF, et al. The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism. Blood...
John Francis Seymour Jr. (born December 3, 1937) is an American retired politician who served as a United States senator from California from 1991 to 1992. A member of the Republican Party , he was appointed to continue Pete Wilson 's term but lost the special election to finish it to Democratic nominee and former San Francisco mayor Dianne ...
28 de mar. de 2024 · John F. Seymour. Blood (2024) 143 (13): 1218–1230. https://doi.org/10.1182/blood.2023022993. Article history. Share. Tools. Abstract. Targeted protein degradation (TPD) is a revolutionary approach to targeted therapy in hematological malignancies that potentially circumvents many constraints of existing small-molecule inhibitors.
9 de sept. de 2021 · Abstract. We report long-term follow-up of the phase 1b study of venetoclax and rituximab (VenR) in patients with relapsed chronic lymphocytic leukemia (CLL), including outcomes with continuous or limited-duration therapy. Patients received venetoclax daily (200-600 mg) and rituximab over 6 months and then received venetoclax monotherapy.
December 8th 2019. John F. Seymour, MBBS, PhD, clinical hematologist, associate director of Clinical Research, Peter MacCallum Centre, director of the integrated Haematology Department of the...
9 de jun. de 2023 · John F. Seymour. First published: 09 June 2023. https://doi.org/10.1002/hon.3146. Sections. PDF. Tools. This section will review the assessment and approved and generally available treatment options for patients with relapsed CLL, including the context of Richter Transformation (the development of diffuse large B-cell lymphoma). 1.
